Lead Product(s): KAN-101
Therapeutic Area: Immunology Product Name: KAN-101
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Bristol-Myers Squibb
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 22, 2020
The collaboration aims developing therapeutics for autoimmune diseases, to include Anokion’s lead antigen-specific drug candidate, KAN-101, for the treatment of celiac disease.
Lead Product(s): PHA121
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2020
The objective of the study was to investigate the ability of PHA121 to attenuate blood-pressure changes induced by bradykinin injection.